Fig. 5.

cAMP-induced full fusions require anchored PKA-R2. (A–H) Frequency of kiss-and-run (KR, black columns) and full fusions (FF, white columns). (A) Frequency of fusions in OK6>Dilp2–FAP boutons treated with H89 without forskolin (−FSK, n=14 NMJs, 132 boutons, six animals) and with forskolin application (+FSK, n=9 NMJs, 100 boutons, five animals). (B) Frequency of fusions in OK6>Dilp2–FAP boutons co-expressing dominant-negative PKA-R1 (PKA-R1 DN) with and without forskolin application (−FSK: n=8 NMJs, 74 boutons, five animals; +FSK: n=14 NMJs, 98 boutons, eight animals). **P<0.01 (unpaired two-tailed t-test). (C) Frequency of fusions in DIPβ>Dilp2–FAP boutons with and without forskolin application (−FSK: n=8 NMJs, 62 boutons, four animals; +FSK: n=9 NMJs, 65 boutons, five animals. **P<0.01 (unpaired two-tailed t-test). (D) Frequency of fusions in DIPβ>Dilp2–FAP boutons also expressing PKA-R2 RNAi with and without forskolin application (−FSK: n=7 NMJs, 50 boutons, four animals; +FSK, n=7 NMJs, 51 boutons, four animals). (E) Frequency of fusions ShakB>Dilp2–FAP boutons co-expressing the Valium20 RNAi control with and without FSK treatment (ShakB) (−FSK, n=8 NMJs, 59 Is boutons, four animals; +FSK: n=10 NMJs, 67 boutons, five animals). (F) Frequency of fusions in ShakB>Dilp2–FAP boutons co-expressing PKA-R2 RNAi (ShakB>R2 RNAi) with and without FSK treatment (−FSK: n=8, 88 Is boutons, four animals; +FSK: n=19 NMJs, 166 boutons, eight animals). (G) Frequency of fusions in St-Ht31 pretreated OK6>Dilp2–FAP boutons with and without FSK treatment (−FSK: n=12 NMJs, 151 boutons, five animals; +FSK: n=20 NMJs, 228 boutons, seven animals). (H) Frequency of fusions in OK6>Dilp2–FAP boutons co-expressing Rugose RNAi (Rg RNAi) with and without FSK (−FSK: n=13 NMJs, 159 boutons, six animals; +FSK: n=11 NMJs, 148 boutons, five animals). No significant difference was found between kiss-and-run fusions frequency in FSK-treated and non-treated boutons (unpaired two-tailed t-test). 1/min, min⁻¹.